Advice

in the absence of a submission from the holder of the marketing authorisation

abatacept (Orencia®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice58KB (PDF)

Download

Medicine details

Medicine name:
abatacept (Orencia)
SMC ID:
1230/17
Indication:
Treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.
Pharmaceutical company
Bristol-Myers Squibb Pharmaceuticals Ltd
BNF chapter
Musculoskeletal and joint diseases
Submission type
Non submission
Status
Not recommended
Date advice published:
13 March 2017